Here are the DEF 14A proxy statements from Cassava Sciences, Inc. (SAVA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SAVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SAVA filings page.
Filana Therapeutics, Inc. is asking stockholders to approve several items at its 2026 virtual annual meeting on June 11, 2026. Stockholders will vote on electing three Class II directors, amending the 2018 Omnibus Incentive Plan, ratifying Ernst & Young LLP as auditor for 2026, and a non-binding advisory vote on 2025 executive compensation.
The equity plan amendment would raise authorized shares from 5,000,000 to 9,000,000, extend the plan’s term to January 31, 2030, tighten annual limits for individual and non‑employee director awards, and add governance features such as an explicit ban on option repricing and a reference to the Dodd-Frank clawback policy. As of April 21, 2026, Filana had 48,307,896 common shares outstanding, and the company estimates total potential dilution from equity plans at about 7.6% if the increase is approved.